ClinicalTrials.gov
public full text
Public Domain
In Vivo PET of Synaptic Density in Cognitive Disorders
This study will compare the discriminative power of \[18F\]-SynVesT-1 PET and the standard-of-care \[18F\]-FDG PET in different cognitive disorders (Alzheimer's disease, Frontotemporal degeneration, dementia with Lewy bodies and late-life psychiatric disorders). Moreover, changes in \[18F\]-SynVesT-1 PET will be evaluated as well as their correlation with specific symptomatology.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Amyloid-PET imaging offers small improvements in predictions of future cognitive trajectories#1174829
- Associations of amyloid-β oligomers and plaques with neuropathology in the App NL-G-F mouse#379303
- Presynaptic accumulation of APP-CTFβ may contribute to synaptic dysfunction in Alzheimer's disease.#1175396
- Brain organoids as models for studying neuropathologies in domestic animals#208771
- Abnormal amyloid PET usually represents intermediate/high Alzheimer's disease neuropathologic change.#161815
Record · ID 1046759
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive